Evaluation of mycoplasma inactivation during production of biologies: ess-based viral vaccines as a model

Applied and Environmental Microbiology

Volumn 76, Issue 9, 2010, Pages 2718-2728

  Wilson David, Selwyn A ^a   Volokhov, Dmitriy V ^a   Ye, Zhiping ^a   Chizhikov, Vladimir ^a  

^a Office of Blood Research and Review   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETYL TRIMETHYL AMMONIUM BROMIDES; CONCENTRATION OF; FORMALIN; INFLUENZA VACCINES; MYCOPLASMA PNEUMONIAE; MYCOPLASMA SPECIES; PHARMACEUTICAL PRODUCTS; POTENTIAL RISKS; PURIFICATION PROCESS; SODIUM DEOXYCHOLATE; TRITON X-100; VIRAL PARTICLES; VIRUS INACTIVATION;

AMMONIUM COMPOUNDS; FORMALDEHYDE; HEALTH RISKS; MANUFACTURE; SODIUM; VIRUSES;

VACCINES;

CETRIMIDE; DEOXYCHOLIC ACID; FORMALDEHYDE; INACTIVATED VACCINE; OCTOXINOL; PROPIOLACTONE; VIRUS VACCINE;

DRUG; EXPERIMENTAL STUDY; FORMALDEHYDE; HEALTH RISK; INFLUENZA; PROBABILITY; PROTEIN; SURFACTANT; VACCINE;

ACHOLEPLASMA LAIDLAWII; ANIMAL; ARTICLE; BIOLOGICAL MODEL; CHEMISTRY; CHICKEN; EGG; ISOLATION AND PURIFICATION; MICROBIAL VIABILITY; MYCOPLASMA; MYCOPLASMA GALLISEPTICUM; MYCOPLASMA PNEUMONIAE; MYCOPLASMA SYNOVIAE; VIROLOGY;

ACHOLEPLASMA LAIDLAWII; ANIMALS; CETRIMONIUM COMPOUNDS; CHICKENS; DEOXYCHOLIC ACID; EGGS; FORMALDEHYDE; MICROBIAL VIABILITY; MODELS, BIOLOGICAL; MYCOPLASMA; MYCOPLASMA GALLISEPTICUM; MYCOPLASMA PNEUMONIAE; MYCOPLASMA SYNOVIAE; OCTOXYNOL; PROPIOLACTONE; VACCINES, INACTIVATED; VIRAL VACCINES;

ACHOLEPLASMA LAIDLAWII; MYCOPLASMA; MYCOPLASMA GALLISEPTICUM; MYCOPLASMA ORALE; MYCOPLASMA PNEUMONIAE; MYCOPLASMA SYNOVIAE; MYCOPLASMATALES;

EID: 77951618044     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.02776-09     Document Type: Article

References (59)

1. Al Masalma, M., F. Armougom, W. M. Scheid, H. Dufour, P. H. Roche, M. Drancourt, and D. Raoult. 2009. The expansion of the microbiological spectrum of brain abscesses with use of multiple 16S ribosomal DNA sequencing. Clin. Infect. Dis. 48: 1169-1178.
2. Anderson, E., S. Clouthier, W. Shewmaker, A. Weighall, and S. LaPatra. 2008. Inactivated infectious haematopoietic necrosis viras (IHNV) vaccines. J. Fish Dis. 31: 729-745.
3. Baczynska, A., H. F. Svenstrup, J. Fedder, S. Birkelund, and G. Christiansen. 2004. Development of real-time PCR for detection of Mycoplasma hominis. BMC Microbiol. 4: 35.
4. Baker, A. S., K. L. Ruoff, and S. Madoff. 1998. Isolation of Mycoplasma species from a patient with seal finger. Clin. Infect. Dis. 27: 1168-1170.
5. Bencina, D., D. Dorrer, and T. Tadina. 1987. Mycoplasma species isolated from six avian species. Avian Pathol. 16: 653-664.
6. Bogomolova, N. N., I. A. Brudno, I. S. Kolianova, N. V. Izotova, and O. E. Orlova. 1981. Study of viral contamination of Japanese quail and cell cultures from their embryos. Vopr. Virusol. 1981: 114-117. (In Russian.)
7. Bogomolova, N. N., N. V. Izotova, S. Boriskin Iu, V. D. Lotte, and I. S. Kolianova. 1978. Isolation and study of several properties of mycoplasma from Japanese quail embryos. Vopr. Virusol. 1978: 560-564. (In Russian.)
8. Budowsky, E. I., E. A. Friedman, and N. V. Zheleznova. 1991. Principles of selective inactivation of viral genome. VII. Some peculiarities in determination of viral suspension infectivity during inactivation by chemical agents. Vaccine 9: 473-476.
9. Budowsky, E. I., E. A. Friedman, N. V. Zheleznova, and F. S. Noskov. 1991. Principles of selective inactivation of viral genome. VI. Inactivation of the infectivity of the influenza virus by the action of beta-propiolactone. Vaccine 9: 398-402.
10. Camara, B., M. Mouzin, D. Ribes, L. Esposito, J. Guitard, X. Game, D. Durand, L. Rostaing, and N. Kamar. 2007. Perihepatitis and perinephric abscess due to Mycoplasma hominis in a kidney transplant patient. Exp. Clin. Transplant. 5: 708-709.
11. Christensen, N. H., C. A. Yavari, A. J. McBain, and J. M. Bradbury. 1994. Investigations into the survival of Mycoplasma gallisepticum, Mycoplasma synoviae and Mycoplasma iowae on materials found in the poultry house environment. Avian Pathol. 23: 127-143.
12. Christianson, G. G., J. R. Pemberton, and T. A. Koski. 1980. Inactivation of mycoplasma in serum with binary ethyleneimine. J. Clin. Microbiol. 11: 377-379.
13. Council of Europe. 2010. Chapter 2.6.7, Mycoplasmas, p. 3317-3321. In European pharmacopoeia 6.1. Council of Europe, Strasbourg, France.
14. Council of Europe. 2010. Chapter 5.2.2, Chicken flocks free from specified pathogens for the production and quality control of vaccines, p. 5137-5139. In European pharmacopoeia 6.6. Council of Europe, Strasbourg, France.
15. Cox, J. H., B. Dietzschold, F. Weiland, and L. G. Schneider. 1980. Preparation and characterization of rabies virus hemagglutinin. Infect. Immun. 30: 572-577.
16. Dobos-Kovacs, M., Z. Varga, G. Czifra, and L. Stipkovits. 2009. Salpingitis in geese associated with Mycoplasma sp. strain 1220. Avian Pathol. 38: 239-243.
17. Frazatti-Gallina, N. M., R. M. Mourao-Fuches, R. L. Paoli, M. L. Silva, C. Miyaki, E. J. Valentini, I. Raw, and H. G. Higashi. 2004. Vero-cell rabies vaccine produced using serum-free medium. Vaccine 23: 511-517.
18. Furuta, K., H. Ohashi, J. Obana, and S. Sato. 1980. Performance of 3 successive generations of specified-pathogenfree chickens maintained as a closed flock. Lab. Anim. 14: 107-112.
19. Garcia-de-la-Fuente, C., E. Minambres, E. Ugalde, A. Saez, L. Martinez-Martinez, and M. C. Farinas. 2008. Post-operative mediastinitis, pleuritis and pericarditis due to Mycoplasma hominis and Ureaplasma urealyticum with a fatal outcome. J. Med. Microbiol. 57: 656-657.
20. Goodburn, G. M., and B. P. Marmion. 1962. A study of the properties of Eaton's primary atypical pneumonia organism. J. Gen. Microbiol. 29: 271-290.
21. Gross, P. A., F. A. Ennis, P. F. Gaerlan, C. R. Denning, U. Setia, W. J. Davis, and D. S. Bisberg. 1981. Comparison of new Triton X-100- and Tween-ethertreated split-treated vaccines in children. J. Clin. Microbiol. 14: 534-538.
22. Gross, P. A., G. V. Quinnan, P. F. Gaerlan, C. R. Denning, M. Lazicki, and M. Bernius. 1983. Influenza vaccines in children. Comparison of new cetrimonium bromide and standard ether-treated vaccines. Am. J. Dis. Child. 137: 26-28.
23. Hannan, P. C. 2000. Guidelines and recommendations for antimicrobial minimum inhibitory concentration (MIC) testing against veterinary mycoplasma species. International Research Programme on Comparative Mycoplasmology. Vet. Res. 31: 373-395.
24. Hayes, M. M., B. J. Li, D. J. Wear, and S. C. Lo. 1996. Pathogenicity of Mycoplasma fermentans and Mycoplasma penetrans in experimentally infected chicken embryos. Infect. Immun. 64: 3419-3424.
25. Jiang, S. D., D. Pye, and J. C. Cox. 1986. Inactivation of polioviras with beta-propiolactone. J. Biol. Stand. 14: 103-109.
26. Jornitz, M. W. 2009. Mycoplasma contamination in culture media. Genet. Eng. Biotechnol. News, http://www.genengnews.com/articles/chtitem.aspx?tid= 2836&chid=3.
27. Kalbfuss, B., Y. Genzel, M. Wolff, A. Zimmermann, R. Morenweiser, and U. Reichl. 2007. Harvesting and concentration of human influenza A virus produced in serum-free mammalian cell culture for the production of vaccines. Biotechnol. Bioeng. 97: 73-85.
28. Kapteyn, J. C., A. M. Porre, E. J. de Rond, W. B. Hessels, M. A. Tijms, H. Kessen, A. M. Slotboom, M. A. Oerlemans, D. Smit, J. van der Linden, P. Schoen, and J. L. Thus. 2009. HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines. Vaccine 27: 1468-1477.
29. 29. Kistner, O., N. Barrett, A. Bruhmann, M. Reiter, W. Mundt, H. Savidis-Dacho, S. Schober-Bendixen, F. Dorner, and J. Aaskov. 2007. The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans. Vaccine 25: 4845-4852. (Pubitemid 46818611)
30. Koski, T. A., G. G. Christianson, and F. L. Cole. 1976. Inactivation of mycoplasmas by use of phenol, formalin and beta-propiolactone. J. Biol. Stand. 4: 151-154.
31. Leroux-Roels, I., and G. Leroux-Roels. 2009. Current status and progress of prepandemic and pandemic influenza vaccine development. Expert Rev. Vaccines 8: 401-423.
32. Levandowski, R. A. 1999. Regulatory perspective in the United States on cell cultures for production of inactivated influenza virus vaccines. Dev. Biol. Stand. 98: 171-175. (Discussion, 98: 197.)
33. Liang, Y., S. Ma, Z. Yang, L. Liu, L. Wang, J. Wang, L. Jiang, C. Shi, C. Dong, and Q. Li. 2008. Immunogenicity and safety of a novel formalininactivated and alum-adjuvanted candidate subunit vaccine for mumps. Vaccine 26: 4276-4283.
34. Lierz, M., and H. M. Hafez. 2008. Time-dependent recovery of Mycoplasma lipofaciens (strain ML64) from incubated infertile chicken eggs and dead in shell chicken embryos. Avian Dis. 52: 441-443.
35. Lierz, M., A. Jansen, and H. M. Hafez. 2008. Avian Mycoplasma lipofaciens transmission to veterinarian. Emerg. Infect. Dis. 14: 1161-1163.
36. Luginbuhl, R. E., R. Holdenried, and R. E. Stevenson. 1969. Establishment and maintenance of a specific pathogen free (SPF) flock of white leghorn chickens. Frog. Immunobiol Stand. 3: 6-13.
37. Madoff, S., B. Q. Pixley, R. A. DelGiudice, and R. C. Moellering, Jr. 1979. Isolation of Mycoplasma bovis from a patient with systemic illness. J. Clin. Microbiol. 9: 709-711.
38. Milne, C., and A. Daas. 2006. Establishment of European pharmacopoeia Mycoplasma reference strains. Pharmeuropa Bio. 2006: 57-72.
39. Moalic, P. Y., I. Kempf, F. Gesbert, and F. Laigret. 1997. Identification of two pathogenic avian mycoplasmas as strains of Mycoplasma pullorum. Int. J. Syst. Bacteriol. 47: 171-174.
40. Pickering, J. M., H. Smith, and C. Sweet. 1992. Influenza virus pyrogenicity: central role of structural orientation of virion components and involvement of viral lipid and glycoproteins. J. Gen. Virol. 73: 1345-1354.
41. Pitcher, D. G., and R. A. Nicholas. 2005. Mycoplasma host specificity: fact or fiction? Vet. J. 170: 300-306.
42. 42. Poon, B., J. T. Safrit, H. McClure, C. Kitchen, J. F. Hsu, V. Gudeman, C. Petropoulos, T. Wrin, I. S. Chen, and K. Grovit-Ferbas. 2005. Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1. J. Virol. 79: 4927-4935. (Pubitemid 40464243)
43. Razin, S., D. Yogev, and Y. Naot. 1998. Molecular biology and pathogenicity of mycoplasmas. Microbiol. Mol. Biol. Rev. 62: 1094-1156.
44. Rosenbusch, R. F., J. M. Kinyon, M. Apley, N. D. Funk, S. Smith, and L. J. Hoffman. 2005. In vitro antimicrobial inhibition profiles of Mycoplasma bovis isolates recovered from various regions of the United States from 2002 to 2003. J. Vet. Diagn. Invest. 17: 436-441.
45. Rottem, S., and M. F. Barile. 1993. Beware of mycoplasmas. Trends Biotechnol. 11: 143-151.
46. Russell, R. G., and G. S. Cottew. 1972. Isolation of Mycoplasma gallisepticum from embryonated chicken eggs. Aust. Vet. J. 48: 425-426.
47. Stenske, K. A., D. A. Bemis, K. Hill, and D. J. Krahwinkel. 2005. Acute polyarthritis and septicemia from Mycoplasma edwardii after surgical removal of bilateral adrenal tumors in a dog. J. Vet. Intern. Med. 19: 768-771.
48. Stipkovits, L., and I. Kempf. 1996. Mycoplasmoses in poultry. Rev. Sci. Tech. 15: 1495-1525.
49. Takase, K., Y. Murakawa, R. Ariyoshi, S. Eriguchi, T. Sugimura, and H. Fujikawa. 2000. Serological monitoring on layer farms with specific pathogen-free chickens. J. Vet. Med. Sci. 62: 1327-1329.
50. Tannock, G. A., D. A. Bryce, M. J. Hensley, N. A. Saunders, R. S. Gillett, and W. S. Kennedy. 1984. Responses to one or two doses of a deoxycholate subunit influenza vaccine in a primed population. Vaccine 2: 100-106.
51. 51. Tano, Y., H. Shimizu, J. Martin, Y. Nishimura, B. Simizu, and T. Miyamura. 2007. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains. Vaccine 25: 7041-7046. (Pubitemid 47470098)
52. Trudel, M., and F. Nadon. 1981. Virosome preparation: differences between influenza and rubella hemagglutinin adsorption. Can. J. Microbiol. 27: 958-962.
53. Twomey, T., J. Newman, T. Burrage, P. Piatti, J. Lubroth, and F. Brown. 1995. Structure and immunogenicity of experimental foot-and-mouth disease and poliomyelitis vaccines. Vaccine 13: 1603-1610.
54. U.S. Food and Drug Administration. 2010. Guidance for industry: characterization and qualification of cell substrates and other biological starting materials used in the production of viral vaccines for the prevention and treatment of infectious diseases. U.S. Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatorylnformation/Guidances/Vaccines /UCM202439.pdf
55. U.S. Food and Drug Administration. 1993. Points to consider in the characterization of cell lines used to produce biologicals (1993). U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologies Evaluation and Research, Rockville, MD. http://www.fda.gov/ downloads/BiologicsBloodVaccines/SafetyAvailability/UCM162863.pdf.
56. van Eck, J. H., N. van Kol, and B. Kouwenhoven. 1980. Egg production in relation to the results of a long term serological survey of 73 flocks of fowl. Tijdschr. Diergeneeskd. 105: 15-24.
57. Volokhov, D. V., J. George, S. X. Liu, P. Ikonomi, C. Anderson, and V. Chizhikov. 2006. Sequencing of the intergenic 16S-23S rRNA spacer (ITS) region of Mollicutes species and their identification using microarray-based assay and DNA sequencing. Appl. Microbiol. Biotechnol. 71: 680-698.
58. Volokhov, D. V., H. Kong, J. George, C. Anderson, and V. E. Chizhikov. 2008. Biological enrichment of Mycoplasma agents by cocultivation with permissive cell cultures. Appl. Environ. Microbiol. 74: 5383-5391.
59. Volokhov, D. V., A. A. Neverov, J. George, H. Kong, S. X. Liu, C. Anderson, M. K. Davidson, and V. Chizhikov. 2007. Genetic analysis of housekeeping genes of members of the genus Acholeplasma: phylogeny and complementary molecular markers to the 16S rRNA gene. Mol. Phylogenet. Evol. 44: 699-710.